Gilead Sciences, Inc.
PD-1/PD-L1 inhibitors
Last updated:
Abstract:
Compounds and methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
Status:
Grant
Type:
Utility
Filling date:
22 Oct 2019
Issue date:
1 Feb 2022